NEW YORK (GenomeWeb News) – Qiagen said after the close of the market on Wednesday that its fourth quarter revenues increased 5 percent year over year at constant exchange rates.

For the three months ended Dec. 31, 2013, the firm posted $362.6 million in revenues, up from $346.5 a year ago, but falling short of the consensus Wall Street estimate of $365.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.